Pili R - Search Results

1

Top2a identifies and provides epigenetic rationale for novel combination therapeutic strategies for aggressive prostate cancer.

Kirk JS, Schaarschuch K, Dalimov Z, Lasorsa E, Ku S, Ramakrishnan S, Hu Q, Azabdaftari G, Wang J, Pili R, Ellis L. Kirk JS, et al. Among authors: pili r. Oncotarget. 2015 Feb 20;6(5):3136-46. doi: 10.18632/oncotarget.3077. Oncotarget. 2015. PMID: 25605014 Free PMC article.

2

Histone deacetylase inhibitors and epigenetic modifications as a novel strategy in renal cell carcinoma.

Ramakrishnan S, Pili R. Ramakrishnan S, et al. Among authors: pili r. Cancer J. 2013 Jul-Aug;19(4):333-40. doi: 10.1097/PPO.0b013e3182a09e07. Cancer J. 2013. PMID: 23867515 Free PMC article. Review.

3

Combinatorial antitumor effect of HDAC and the PI3K-Akt-mTOR pathway inhibition in a Pten defecient model of prostate cancer.

Ellis L, Ku SY, Ramakrishnan S, Lasorsa E, Azabdaftari G, Godoy A, Pili R. Ellis L, et al. Among authors: pili r. Oncotarget. 2013 Dec;4(12):2225-36. doi: 10.18632/oncotarget.1314. Oncotarget. 2013. PMID: 24163230 Free PMC article.

4

Inhibition of Hsp90 augments docetaxel therapy in castrate resistant prostate cancer.

Ku S, Lasorsa E, Adelaiye R, Ramakrishnan S, Ellis L, Pili R. Ku S, et al. Among authors: pili r. PLoS One. 2014 Jul 29;9(7):e103680. doi: 10.1371/journal.pone.0103680. eCollection 2014. PLoS One. 2014. PMID: 25072314 Free PMC article.

5

Genomic profiling is predictive of response to cisplatin treatment but not to PI3K inhibition in bladder cancer patient-derived xenografts.

Wei L, Chintala S, Ciamporcero E, Ramakrishnan S, Elbanna M, Wang J, Hu Q, Glenn ST, Murakami M, Liu L, Gomez EC, Sun Y, Conroy J, Miles KM, Malathi K, Ramaiah S, Anbarasu A, Woloszynska-Read A, Johnson CS, Conroy J, Liu S, Morrison CD, Pili R. Wei L, et al. Among authors: pili r. Oncotarget. 2016 Nov 22;7(47):76374-76389. doi: 10.18632/oncotarget.13062. Oncotarget. 2016. PMID: 27823983 Free PMC article.

6

Histone Deacetylase Inhibitors: Advancing Therapeutic Strategies in Hematological and Solid Malignancies.

Ellis L, Pili R. Ellis L, et al. Among authors: pili r. Pharmaceuticals (Basel). 2010 Aug 1;3(8):2411-2469. doi: 10.3390/ph3082441. Pharmaceuticals (Basel). 2010. PMID: 21151768 Free PMC article.

7

Development of a castrate resistant transplant tumor model of prostate cancer.

Ellis L, Lehet K, Ramakrishnan S, Adelaiye R, Pili R. Ellis L, et al. Among authors: pili r. Prostate. 2012 May 1;72(6):587-91. doi: 10.1002/pros.21465. Epub 2011 Jul 27. Prostate. 2012. PMID: 21796655 Free PMC article.

8

Vascular disruption in combination with mTOR inhibition in renal cell carcinoma.

Ellis L, Shah P, Hammers H, Lehet K, Sotomayor P, Azabdaftari G, Seshadri M, Pili R. Ellis L, et al. Among authors: pili r. Mol Cancer Ther. 2012 Feb;11(2):383-92. doi: 10.1158/1535-7163.MCT-11-0748. Epub 2011 Nov 14. Mol Cancer Ther. 2012. PMID: 22084164 Free PMC article.

9

Concurrent HDAC and mTORC1 inhibition attenuate androgen receptor and hypoxia signaling associated with alterations in microRNA expression.

Ellis L, Lehet K, Ramakrishnan S, Adelaiye R, Miles KM, Wang D, Liu S, Atadja P, Carducci MA, Pili R. Ellis L, et al. Among authors: pili r. PLoS One. 2011;6(11):e27178. doi: 10.1371/journal.pone.0027178. Epub 2011 Nov 7. PLoS One. 2011. PMID: 22087262 Free PMC article.

10

Histone modifications: implications in renal cell carcinoma.

Ramakrishnan S, Ellis L, Pili R. Ramakrishnan S, et al. Among authors: pili r. Epigenomics. 2013 Aug;5(4):453-62. doi: 10.2217/epi.13.40. Epigenomics. 2013. PMID: 23895657 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

236 results

Search Page

Filters